Somatotrope pituitary adenomas. Contribution of presurgical treatment with somatostatin analogs;Adenomes hypophysaires somatotropes. Interet d'un traitement pre- chirurgical par analogues de la somatostatine

Annales d'Endocrinologie

Volumn 60, Issue 6, 1999, Pages 490-493

  Sadoul, J L ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Acromegaly; Somatostatin analogs; Somatotrope pituitary adenomas

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; DRUG DERIVATIVE; HUMAN GROWTH HORMONE; SOMATOSTATIN;

ACROMEGALY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GROWTH HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; MICROADENOMA; REVIEW; RISK BENEFIT ANALYSIS; TUMOR VOLUME; ADENOMA; HYPOPHYSIS TUMOR; PREMEDICATION; SECRETION;

ADENOMA; HUMAN GROWTH HORMONE; HUMANS; OCTREOTIDE; PITUITARY NEOPLASMS; PREMEDICATION; SOMATOSTATIN;

EID: 0033386909     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. RAZZORE P, COLAO A, BALDELLI R et al. Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients : A retrospective study. Clin Endocrinol 1999; 51: 159-64.
2. TAMURA M, YOKOYAMA N, ABE Y et al. Preoperative treatment of growth hormone-producing pituitary adenoma with continuous subcutaneous infusion of octreotide. Endocrin J 1998; 45: 269-75.
3. PLOCKINGER U, REICHEL M, FETT U, SAEGER W, QUABBE HJ. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas : Effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 1994; 79: 1416-23.
4. TOLIS G . The role of somatostatin agonistic analogs in the treatment of acromegaly. Metabolism : Clinical & Experimental 1996; 45 (Suppl 8): 109-10.
5. STEVENAERT A, BECKERS A. Presurgical octreotide : Treatment in acromegaly. Metabolism 1996; 45 (Suppl 8): 72-4.
6. MELMED S. Medical management of acromegaly. What and when. Acta Endocrinologica 1993; 129 : 13-17.
7. LUCAS-MORANTE T, GARCIA-URIA J, ESTRADA J et al. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transphenoidal surgery. J Neurosurg 1994; 81: 10-14.
8. ZGLICZYNSKI W, ZGLICZYNSKI S, JESKE W, BONICKI W, PODGORSKI J, KROLICKI L. The somatostatin analog (SR-Lanreotide) pretreatment improves surgical outcome in acromegalic patients harbouring pituitary tumors with somatostatin receptors. J Endocrinol Invest 1997; 20 (Suppl to no 7):45-7.
9. COLAO A, FERONE D, CAPPABIANCA P et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1997; 82 : 3308-14.
10. KRISTOF RA, STOFFEL WAGNER B, KLINGMULLER D et al. Does octreotide treatment improve the surgical results of macroadenomas in acromegaly? A randomized study. Acta Neurochir 1999; 141: 399-405
11. BIERMASZ N R, VAN DUKEN H, ROELFSEMA F. Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalie patients pretreated with octreotide compared to those in untreated matched controls. J Clin Endocrinol Metab 1999;84: 3551-5.